Exane Derivatives’s Autolus Therapeutics AUTL Stock Holding History

Exane Derivatives’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$509	Hold	180	–	–	﹤0.01%	569
2022 Q1	$751	Hold	180	–	–	﹤0.01%	831
2021 Q4	$934	Hold	180	–	–	﹤0.01%	717
2021 Q3	$1.18K	Hold	180	–	–	﹤0.01%	842
2021 Q2	$1.14K	Hold	180	–	–	﹤0.01%	860
2021 Q1	$1.03K	Hold	180	–	–	﹤0.01%	733
2020 Q4	$1.61K	Hold	180	–	–	﹤0.01%	645
2020 Q3	$2.1K	Hold	180	–	–	﹤0.01%	560
2020 Q2	$2.88K	Hold	180	–	–	﹤0.01%	482
2020 Q1	$1.08K	Hold	180	–	–	﹤0.01%	541
2019 Q4	$2.29K	Sell	180 -2,908	-94%	-$38.1K	﹤0.01%	487
2019 Q3	$38.3K	Hold	3,088	–	–	0.01%	378
2019 Q2	$49.7K	Buy	+3,088	New	+$69.1K	0.01%	391

Other funds holding AUTL

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Exane Derivatives's AUTL Position: Q2 2022 in Review

Exane Derivatives held its Autolus Therapeutics (AUTL) position steady in Q2 2022 at 180 shares worth $509. The position accounts for ﹤0.01% of the portfolio, ranked #569.

Exane Derivatives first reported a position in AUTL in Q2 2019 and has held it in 13 quarters since. The position peaked at $49.7K in Q2 2019. 67 funds tracked by Wall St. Rank hold AUTL as of Q2 2022.

Exane Derivatives held 180 shares of Autolus Therapeutics worth $509 as of Q2 2022.
Exane Derivatives left its Autolus Therapeutics share count unchanged in Q2 2022.
Autolus Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #569 holding.
Exane Derivatives first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 13 quarters since.
Exane Derivatives's Autolus Therapeutics position peaked at $49.7K in Q2 2019.
67 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.